Deep Brain Stimulation of the Subthalamic Nucleus: Clinical Effectiveness and Safety
Neurol 56:552-554, Lopiano,L.,et al, 2001
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
MR Imaging Findings After Stereotactic Radiosurgery Using the Gamma Knife
AJR 176:1589-1595, Friedman,D.P.,et al, 2001
DBS and Diathermy Interaction Induces Severe CNS Damage
Neurol 56:1384-1386, Nutt,J.G.,et al, 2001
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson's Disease Patients' Relatives with a Decreased Sense of Smell
Ann Neurol 50:34-41, Berendse,H.W.,et al, 2001
Reversible Parkinsonism and MRI Diffusion Abnormalities in Cortical Venous Thrombosis
Neurol 57:364-366, Jenkins,M.,et al, 2001
Effects of Bilateral Subthalamic Nucleus Stimulation on Parkinsonian Gait
Neurol 57:144-146, Stolze,H.,et al, 2001
Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease
Arch Neurol 58:1223-1227,1205, Alegret,M.,et al, 2001
Bilateral Pallidal Deep Brain Stimulation for Cervical and Truncal Dystonia
Neurol 57:557-558, Andaluz,N.,et al, 2001
Deep Brain Stimulation in the Treatment of Parkinson's Disease,A Cost-Effectiveness Analysis
Neurol 57:663-671, Tomaszewski,K.J.&Holloway,R.G., 2001
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
A randomized,Double-blind,Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol 58:1385-1392, Dewey,R.B.,et al, 2001
Essential Tremor
NEJM 345:887-891, Louis,E.D., 2001
Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease
NEJM 345:956-963, The Deep-Brain Stimulation for Parkinson's Disease, 2001
Improved Accuracy of Clinical Diagnosis of Lewy Body Parkinson's Disease
Neurol 57:1497-1499, Hughes,A.J.,et al, 2001
Daytime Sleepiness and Other Sleep Disorders in Parkinson's Disease
Neurol 57:1392-1396, Ondo,W.G.,et al, 2001
Hallucinations in Parkinson's Disease
Lancet 358:1031-1032, Korczyn,A.D., 2001
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Tourette's Syndrome Improvement with Pergolide in a Randomized, Double-Blind, Crossover Trial
Neurol 54:1310-1315, Gilbert,D.L.,et al, 2000
Progression of Parkinsonian Signs in Alzheimer's Disease
Neurol 54:1284-1289, Wilson,R.S.,et al, 2000
Botulinum Toxin A as Treatment for Drooling Saliva in PD
Neurol 54:244-247, Pal,P.K.,et al, 2000
The Nonmotor Problems of Parkinson's Disease
The Neurologist 6:18-27, Friedman,J.H.&Fernandez,H.H., 2000
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Failure of Long-Term Pallidal Stimulation Corrected by Subthalmaic Stimulation in PD
Neurol 55:728-730, Houeto,J.L. et al, 2000
Olanzapine and Clozapine Comparative Effects on Motor Function in Hallucinating PD Patients
Neurol 55:789-794, 748, Goetz,C.F. et al, 2000
Computerized Posturography Analysis of Progressive Suprnuclear Palsy
Arch Neurol 57:1464-1469, Ondo,W.,et al, 2000
Acute Orhtostatic Hypotension When Starting Dopamine Agonists in Parkinson's Disease
Arch Neurol 57:1461-1463, Kujawa,K.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Motor and Cognitive Improvements in Patients with Huntington's Disease after Neurol Trasnplantation
Lancet 356:1975-1979,1945, Bachoud-Levi,A.,et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Selegiiline and Mortality in Subjects with Parkinson's Disease
Neurol 55:1785-1789,1770, Donnan,P.T.,et al, 2000
A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor
NEJM 342:461-468,505, Schuurman,P.R.,et al, 2000
Objective Changes in Motor Function During Placebo Treatment in PD
Neurol 54:710-714, Goetz,C.G.,et al, 2000
Effects of Bilateral Posteroventral Pallidotomy on Gait of Subjects with Parkinson Disease
Arch Neurol 57:198-204, Siegel,K.L.&Metman,L.V., 2000
Long-Term Follow-Up of Unilateral Pallidotomy in Advanced Parkinson's Disease
NEJM 342:1708-1714, Fine,J.,et al, 2000
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Association Between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
NEJM 342:1560-1567, Lucking,C.B.,et al, 2000
Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease
JAMA 283:2674-2679, Ross,G.W.,et al, 2000
Depression in Parkinson's Disease
BMJ 320:1287-1288, Allain,H.,et al, 2000
Clinical Characteristics of Pramipexole-Induced Peripheral Edema
Arch Neurol 57:729-732, Tan,E.K.&Ondo,W., 2000
Axial Parkinsonian Symptoms Can Be Improved: The Role of Levodopa and Bilateral Subthalamic Stimulation
JNNP 68:595-600, Bejjani,B.P.,et al, 2000
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
The Catechol-O-Methyltransferase (COMT) Inhibitor Entacapone Enhances the Pharmacokinetic and Clinical Response to Sinemet CR in Parkinson's Disease
JNNP 68:589-594, Piccinni,P.,et al, 2000
Structural Changes of the Substantia Nigra in Parkinson's Disease as Revealed by MR Imaging
AJNR 21:697-701, Hutchinson,M.&Raff,U., 2000
Functional Outcomes After Gamma Knife Thalamotomy for Essential Tremor and MS-Related Tremor
Neurol 55:443-446, Niranjan,A. et al, 2000
Deep Brain Stimulation of Subthalamic Area for Severe Proximal Tremor
Neurol 55:114-116, Kitagawa,M. et al, 2000
Surgery for Parkinson Disease
Arch Neurol 57:1118-1125, Lang,A.E., 2000
Health-Related Quality of Life in Neurology
Arch Neurol 57:1224-1227, Meyers,A.R. et al, 2000